Skip to content

house · Committee report

H. Rept. 119-706

FDA MODERNIZATION ACT 3.0

2026-06-18

Committees

Associated legislation

Text

Purpose and Summary

H.R. 2821 requires the Secretary of Health and Human Services (HHS) to publish an interim final rule amending certain regulations to replace references to ``animal'' tests, data, studies, models, and research with references to ``nonclinical'' tests, data, studies, models, and research.

Background and Need for Legislation

Biomedical research frequently employs animal models to investigate biological processes, analyze diseases, and explore potential therapies. In drug development, researchers have traditionally tested safety of drugs in animals before starting human clinical trials.\1\ While animal studies can reliably predict some human responses and side effects,\2\ they may not provide a comprehensive prediction of how humans might react to medications or of the overall effects a drug could have on human health. This is especially true regarding the ability of animal models to predict the effectiveness of drugs for conditions such as cancer, Alzheimer's, and inflammatory diseases.\3\ --------------------------------------------------------------------------- \1\Food and Drug Administration (FDA), Reducing Animal Testing in Nonclinical Studies: Year One Progress and the Path Forward at 2 (Apr. 20, 2026), https://www.fda.gov/media/191986/download?attachment. \2\Michael C.J. Chang & Franziska B. Grieder, LAB ANIMAL, The continued importance of animals in biomedical research (2024). \3\FDA, Roadmap to Reducing Animal Testing in Preclinical Safety Studies at 1 (April 10, 2025), https://www.fda.gov/media/186092/ download?attachment. --------------------------------------------------------------------------- Due to ethical concerns and the scientific limitations of animal testing in research, the scientific community has increasingly considered development and use of new approach methodologies (NAMs), which are novel tools to assess drug safety, efficacy, and pharmacology without traditional animal models.\4\ According to the Food and Drug Administration (FDA), NAMs encompass a variety of testing methods and strategies, including in vitro and human-based systems, in silico and computational modeling tools, as well as other emerging technologies and innovative platforms.\5\ --------------------------------------------------------------------------- \4\FDA, New Approach Methodologies (NAMs) (Apr. 20, 2026), https:// www.fda.gov/science- research/science-and-research-special-topics/new-approach- methodologies-nams#activities. \5\FDA, supra note 2 at 1-4. --------------------------------------------------------------------------- Congress has directed federal agencies to seek alternatives to animal testing for safety and efficacy assessments when scientifically justified.\6\ The existing federal policy framework reflects decades of efforts to strike the right balance between animal welfare concerns and the value of animal tests in scientific research.\7\ --------------------------------------------------------------------------- \6\Eleni G. Bickell & Kavya Sekar, CONG. RSCH. SERV. (CRS), IF120002, Animal Use in Federal Biomedical Research: A Policy Overview (2023). \7\Id. --------------------------------------------------------------------------- In 2022, Congress passed the FDA Modernization Act 2.0, as part of the Consolidated Appropriations Act of 2023.\8\ This legislation amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to authorize the use of non-animal alternatives to support investigational new drug (IND) applications and removed a requirement to include animal studies in biosimilar biologic license applications (BLAs).\9\ However, FDA has not yet made conforming changes to the relevant regulations to implement the changes made under that Act. --------------------------------------------------------------------------- \8\Consolidated Appropriations Act, 2023, Pub. L. No. 117-328, 136 Stat. 4459 (2022). \9\FDA, supra note 2 at 1. --------------------------------------------------------------------------- H.R. 2821, the FDA Modernization Act 3.0, would require HHS, the agency under which the FDA falls, to publish an interim final rule to amend certain regulations to replace references of ``animal'' tests, data, studies, models, and research with references to ``nonclinical'' tests, data, studies, models, and research. The FDA Modernization Act 3.0 was first introduced in February 2024 during the 118th Congress. It was reintroduced in April 2025, during the 119th Congress, as H.R. 2821. The FDA also released its ``Roadmap to Reduce Animal Testing'' in April 2025 and outlined its plan for reducing preclinical safety animal testing by using validated NAMs.\10\ --------------------------------------------------------------------------- \10\Press Release, FDA, FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs (Apr. 10, 2025), https://www.fda.gov/news-events/press-announcements/fda- announces-plan-phase-out-animal-testing-requirement-monoclonal- antibodies-and-other-drugs. ---------------------------------------------------------------------------

Committee Action

On July 16, 2025, the Subcommittee on Health held a legislative hearing on H.R. 2821. The Subcommittee received testimony from: Jacqueline Corrigan-Curay, JD, MD, Acting Director for Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration; Candice Chen, MD, MPH, Acting Associate Administrator for Health Workforce, U.S. Health Resources and Services Administration; and Tom Morris, MPA, Associate Administrator for Rural Health Policy, U.S. Health Resources and Services Administration. On May 13, 2026, the Subcommittee on Health met in open markup session and forwarded H.R. 2821, without amendment, to the full Committee by a voice vote. On May 21, 2026, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 2821, without amendment, favorably reported to the House by a record vote of 44 yeas and 0 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 2821 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to require the Secretary to publish an interim final rule to amend certain regulations to replace references of animal tests, data, studies, models, and research with nonclinical references to these items. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 2821 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 2821: On July 16, 2025, the Subcommittee on Health held a legislative hearing on H.R. 2821. The title of the hearing was ``Legislative Proposals to Maintain and Improve the Public Health Workforce, Rural Health, and Over-the-Counter Medicines.'' The Subcommittee received testimony from: Jacqueline Corrigan-Curay, JD, MD, Acting Director for Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration; Candice Chen, MD, MPH, Acting Associate Administrator for Health Workforce, U.S. Health Resources and Services Administration; and Tom Morris, MPA, Associate Administrator for Rural Health Policy, U.S. Health Resources and Services Administration. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 2821 contains no earmarks, limited tax benefits, or limited tariff benefits Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title Section 1 provides a short title of ``FDA Modernization Act 3.0.'' Section 2. Regulations on nonclinical testing methods Section 2 requires the Secretary to publish an interim final rule no later than one year after the enactment of H.R. 2821 to amend certain sections (listed in the bill text) of title 21 of the Code of Federal Regulations, replacing references to ``animal'' tests, data, studies, models, and research with references to ``nonclinical'' tests, data, studies, models, and research. The interim final rule must also add the definition of ``nonclinical test,'' located in section 505(z) of the FD&C Act, to specific sections (also listed) of title 21 of the Code of Federal Regulations. Additionally, section 2 specifies that the interim final rule issued by HHS shall take effect immediately as an interim final rule, without requiring the Secretary to demonstrate good cause. Finally, this section includes a technical amendment to section 505 of the FD&C Act to designate the second subsection (z), which relates to clinical trial diversity action plans, as added by section 3601(a) of the Health Extenders, Improving Access to Medicare, Medicaid, and CHIP, and Strengthening Public Health Act of 2022, as subsection (aa). Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): FEDERAL FOOD, DRUG, AND COSMETIC ACT * * * * * * * CHAPTER V--DRUGS AND DEVICES Subchapter A--Drugs and Devices * * * * * * * new drugs Sec. 505. (a) No person shall introduce or deliver for introduction into interstate commerce any new drug, unless an approval of an application filed pursuant to subsection (b) or (j) is effective with respect to such drug. (b) (b)(1)(A) Any person may file with the Secretary an application with respect to any drug subject to the provisions of subsection (a). Such persons shall submit to the Secretary as part of the application-- (i) full reports of investigations which have been made to show whether such drug is safe for use and whether such drug is effective in use; (ii) a full list of the articles used as components of such drug; (iii) a full statement of the composition of such drug; (iv) a full description of the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such drug; (v) such samples of such drug and of the articles used as components thereof as the Secretary may require; (vi) specimens of the labeling proposed to be used for such drug; (vii) any assessments required under section 505B; and (viii) the patent number and expiration date of each patent for which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug, and that-- (I) claims the drug for which the applicant submitted the application and is a drug substance (active ingredient) patent or a drug product (formulation or composition) patent; or (II) claims a method of using such drug for which approval is sought or has been granted in the application. (B) If an application is filed under this subsection for a drug, and a patent of the type described in subparagraph (A)(viii) is issued after the filing date but before approval of the application, the applicant shall amend the application to include the patent number and expiration date. (2) An application submitted under paragraph (1) for a drug for which the investigations described in clause (A) of such paragraph and relied upon by the applicant for approval of the application were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted shall also include-- (A) a certification, in the opinion of the applicant and to the best of his knowledge, with respect to each patent which claims the drug for which such investigations were conducted or which claims a use for such drug for which the applicant is seeking approval under this subsection and for which information is required to be filed under paragraph (1) or subsection (c)-- (i) that such patent information has not been filed, (ii) that such patent has expired, (iii) of the date on which such patent will expire, or (iv) that such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted; and (B) if with respect to the drug for which investigations described in paragraph (1)(A) were conducted information was filed under paragraph (1) or subsection (c) for a method of use patent which does not claim a use for which the applicant is seeking approval under this subsection, a statement that the method of use patent does not claim such a use. (3) Notice of opinion that patent is invalid or will not be infringed.-- (A) Agreement to give notice.--An applicant that makes a certification described in paragraph (2)(A)(iv) shall include in the application a statement that the applicant will give notice as required by this paragraph. (B) Timing of notice.--An applicant that makes a certification described in paragraph (2)(A)(iv) shall give notice as required under this paragraph-- (i) if the certification is in the application, not later than 20 days after the date of the postmark on the notice with which the Secretary informs the applicant that the application has been filed; or (ii) if the certification is in an amendment or supplement to the application, at the time at which the applicant submits the amendment or supplement, regardless of whether the applicant has already given notice with respect to another such certification contained in the application or in an amendment or supplement to the application. (C) Recipients of notice.--An applicant required under this paragraph to give notice shall give notice to-- (i) each owner of the patent that is the subject of the certification (or a representative of the owner designated to receive such a notice); and (ii) the holder of the approved application under this subsection for the drug that is claimed by the patent or a use of which is claimed by the patent (or a representative of the holder designated to receive such a notice). (D) Contents of notice.--A notice required under this paragraph shall-- (i) state that an application that contains data from bioavailability or bioequivalence studies has been submitted under this subsection for the drug with respect to which the certification is made to obtain approval to engage in the commercial manufacture, use, or sale of the drug before the expiration of the patent referred to in the certification; and (ii) include a detailed statement of the factual and legal basis of the opinion of the applicant that the patent is invalid or will not be infringed. (4)(A) An applicant may not amend or supplement an application referred to in paragraph (2) to seek approval of a drug that is a different drug than the drug identified in the application as submitted to the Secretary. (B) With respect to the drug for which such an application is submitted, nothing in this subsection or subsection (c)(3) prohibits an applicant from amending or supplementing the application to seek approval of a different strength. (5)(A) The Secretary shall issue guidance for the individuals who review applications submitted under paragraph (1) or under section 351 of the Public Health Service Act, which shall relate to promptness in conducting the review, technical excellence, lack of bias and conflict of interest, and knowledge of regulatory and scientific standards, and which shall apply equally to all individuals who review such applications. (B) The Secretary shall meet with a sponsor of an investigation or an applicant for approval for a drug under this subsection or section 351 of the Public Health Service Act if the sponsor or applicant makes a reasonable written request for a meeting for the purpose of reaching agreement on the design and size-- (i)(I) of clinical trials intended to form the primary basis of an effectiveness claim; or (II) in the case where human efficacy studies are not ethical or feasible, of animal and any associated clinical trials which, in combination, are intended to form the primary basis of an effectiveness claim; or (ii) with respect to an application for approval of a biological product under section 351(k) of the Public Health Service Act, of any necessary clinical study or studies. The sponsor or applicant shall provide information necessary for discussion and agreement on the design and size of the clinical trials. Minutes of any such meeting shall be prepared by the Secretary and made available to the sponsor or applicant upon request. (C) Any agreement regarding the parameters of the design and size of clinical trials of a new drug under this paragraph that is reached between the Secretary and a sponsor or applicant shall be reduced to writing and made part of the administrative record by the Secretary. Such agreement shall not be changed after the testing begins, except-- (i) with the written agreement of the sponsor or applicant; or (ii) pursuant to a decision, made in accordance with subparagraph (D) by the director of the reviewing division, that a substantial scientific issue essential to determining the safety or effectiveness of the drug has been identified after the testing has begun. (D) A decision under subparagraph (C)(ii) by the director shall be in writing and the Secretary shall provide to the sponsor or applicant an opportunity for a meeting at which the director and the sponsor or applicant will be present and at which the director will document the scientific issue involved. (E) The written decisions of the reviewing division shall be binding upon, and may not directly or indirectly be changed by, the field or compliance division personnel unless such field or compliance division personnel demonstrate to the reviewing division why such decision should be modified. (F) No action by the reviewing division may be delayed because of the unavailability of information from or action by field personnel unless the reviewing division determines that a delay is necessary to assure the marketing of a safe and effective drug. (G) For purposes of this paragraph, the reviewing division is the division responsible for the review of an application for approval of a drug under this subsection or section 351 of the Public Health Service Act (including all scientific and medical matters, chemistry, manufacturing, and controls). (6) An application submitted under this subsection shall be accompanied by the certification required under section 402(j)(5)(B) of the Public Health Service Act. Such certification shall not be considered an element of such application. (7) Rx-to-nonprescription switches.-- (A) Meetings.--Any person planning to submit an application for an Rx-to-nonprescription switch may submit to the Secretary a written request for a meeting, for purposes of developing a plan for such application that addresses the potential risks to public health of such switch and the evidence necessary to support such application, including the design of any necessary studies, and the format and content of the planned application. The Secretary may grant such a meeting, as appropriate, consistent with established procedures for granting meetings with, and providing written responses to, applications under this section. Each such meeting shall be documented in meeting minutes. (B) Guidance.-- (i) In general.--Not later than 18 months after the date of enactment of this paragraph, the Secretary shall issue guidance to increase the clarity and predictability of the process and standards for approval of applications for nonprescription drugs under this section, including in the case of applications for an Rx-to- nonprescription switch, especially with respect to prescription drugs with well-established safety profiles for which an applicant may seek approval for nonprescription use. (ii) Contents.--The guidance under clause (i) shall-- (I) describe how published reports in medical literature, any previous finding of safety or effectiveness for the drug under this section, the results of significant human experience with the drug, unpublished studies and other data, and other sources of information may be used to support an application for a nonprescription drug, including in the context of an application for an Rx-to- nonprescription switch; (II) set forth procedures for sponsors to request meetings described in subparagraph (A) and document the recommendations made in such meetings; (III) describe evidentiary expectations to support approval of an application for a nonprescription drug, i

Source: https://api.congress.gov/v3/committee-report/119/hrpt/706